clinical trial · NCT03987802
An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice
Novo Nordisk A/S·—·completed·n = 42
Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Faster-acting insulin aspart
brief summary
This study is to investigate the effects of Fiasp®, a mealtime insulin, in patients with diabetes mellitus. The purpose of this study is to collect information about Fiasp®, which is prescribed to the participants by their doctors. Participants will administer Fiasp® as prescribed by their doctors. The study will last for about 6 months.
started
Jan 20, 2021
primary completion
Jun 28, 2022
completion
Jun 28, 2022
last updated
Apr 9, 2026
official title
An Indian Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Post Marketing Surveillance Study of Fiasp® to Evaluate Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol